On October 1, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported recent media coverage focused on the Company’s development strategy for Ampligen (rintatolimod) in metastatic pancreatic cancer, including the scientific rationale for targeting immune resistance and the continued advancement of the Phase 2 DURIPANC clinical trial ("DURIPANC").
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Recent coverage includes:
Med World News: AIM ImmunoTech’s Ampligen Program Targets One of Pancreatic Cancer’s Hardest Barriers
Pharma Tech News: Inside AIM ImmunoTech’s Ampligen Strategy for Targeting Immune Resistance in Pancreatic Cancer
Pancreatic cancer remains one of the most difficult cancers to treat, in part because of an immunosuppressive tumor microenvironment that can limit the effectiveness of immune-based therapies. Recent features have examined Ampligen’s potential to help address this challenge through its immune-modulating activity and the rationale for evaluating the drug in combination with checkpoint inhibition.
AIM successfully concluded a Netherlands-approved Named Patient Program ("NPP") in which 57 patients with radiologically stable pancreatic cancer after FOLFIRINOX received Ampligen as a maintenance treatment, with highly encouraging findings of Overall Survival, safety and improved Quality of Life. Ampligen is also being evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) in the Phase 2 DURIPANC clinical trial in metastatic pancreatic cancer, with interim reports of immune system changes that suggest a coordinated activation of innate and adaptive responses, and all while the combination therapy is reported as being well-tolerated and patients consistently report a high Quality of Life throughout treatment. The study has completed final Ampligen dosing, representing an important clinical milestone as the program advances toward topline results expected in the first quarter of 2027.
"The recent media attention around Ampligen reflects the important scientific rationale behind our pancreatic cancer strategy, supported by the meaningful clinical progress we have made with DURIPANC," said AIM Chief Executive Officer Thomas K. Equels. "With DURIPANC final Ampligen dosing complete and topline results expected in the first quarter of 2027, we are approaching an important inflection point for the program. We believe that the NPP data combined with the upcoming DURIPANC data – including exploratory biomarker analyses that may help AIM to better understand patient response – will provide important insight into Ampligen’s potential role in metastatic pancreatic cancer and help inform the design of a planned pivotal clinical trial."
(Press release, AIM ImmunoTech, OCT 1, 2026, View Source [SID1234671210])